mavacamten - Profile

What are the generic drug sources for mavacamten and what is the scope of patent protection?

Mavacamten is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mavacamten has sixty-seven patent family members in thirty-nine countries.

Summary for mavacamten

International Patents:	67
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mavacamten

Constraining patent/regulatory exclusivity:

RE50050

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for mavacamten

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No	9,585,883
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No	RE50050		Y	Y
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No

EU/EMA Drug Approvals for mavacamten

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Camzyos	mavacamten	EMEA/H/C/005457Treatment of symptomatic obstructive hypertrophic cardiomyopathy.	Authorised	no	no	no	2023-06-26

International Patents for mavacamten

Country	Patent Number	Title	Estimated Expiration
Canada	2915967	COMPOSES DE PYRIMIDINE-DIONE CONTRE LES AFFECTIONS CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Lithuania	3010910
European Patent Office	3010910	COMPOSÉS PYRIMIDINEDIONE CONTRE LES MALADIES CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Ukraine	117929	СПОЛУКИ ПІРИМІДИНДІОНУ, СПРЯМОВАНІ ПРОТИ СТАНІВ СЕРЦЕВО-СУДИННОЇ СИСТЕМИ (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)

Supplementary Protection Certificates for mavacamten

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3010910	23C1047	France		PRODUCT NAME: MAVACAMTEN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1716 20230627
3010910	C20230036	Finland
3010910	2023C/546	Belgium		PRODUCT NAME: MAVACAMTEN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1716 20230627
3010910	C202330045	Spain		PRODUCT NAME: MAVACAMTEN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1716; DATE OF AUTHORISATION: 20230626; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1716; DATE OF FIRST AUTHORISATION IN EEA: 20230626

Mavacamten: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary
Mavacamten, developed by MyoKardia (a Bristol-Myers Squibb company since 2020), is a selective cardiac myosin inhibitor approved in the U.S. for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The drug has demonstrated potential for significant market penetration due to the lack of targeted therapies for oHCM. This report examines the current market landscape, investment opportunities, revenue projections, competitive environment, and strategic considerations for mavacamten, providing a comprehensive outlook for stakeholders.

---

1. What Is the Current Investment Scenario for Mavacamten?

Development and Regulatory Status

• Regulatory approvals: FDA approved mavacamten (brand name Mydayis) for symptomatic oHCM in April 2022 (FDA Calendar Year) [1].
• Market authorization: Also approved in Europe (EMA approval in 2023).
• Pipeline: Ongoing studies for non-obstructive HCM, heart failure with preserved ejection fraction (HFpEF), and cardiovascular conditions.
• Partnerships: Bristol-Myers Squibb acquired MyoKardia at $13.1 billion in 2020, consolidating investment in mavacamten’s market potential.[2]

Investment Considerations

• Market exclusivity: 12-year data exclusivity under U.S. law, with potential for additional patent extensions.
• Pricing strategies: Current wholesale acquisition cost (WAC) set at approximately $10,000/month.
• Reimbursement environment: Favorable due to unmet clinical need; insurance coverage varies but generally positive post-approval.
• Market entry barriers: Clinical adoption, physician awareness, and competitive therapies pose initial hurdles.

---

2. What Are the Market Dynamics Affecting Mavacamten?

Target Patient Population

Metric	Data	Source
Prevalence of HCM	1 in 500 worldwide	[3]
Obstructive HCM subset (oHCM)	~60% of HCM cases	[4]
Estimated U.S. Patients	~45,000	(Prevalence x U.S. adult population)

Market Drivers

• Unmet medical need: No approved pharmacotherapy specifically targeting the underlying mechanism of oHCM.
• Approved indications: Symptomatic relief, reduce obstruction, potentially delay surgical interventions (septal myectomy).
• Physician adoption: Driven by clinical trial data demonstrating improved exercise capacity and symptom reduction.
• Reimbursement policies: Increasing acceptance of innovative cardiovascular drugs enhances market penetration potential.

Market Challenges

• Pricing and payor policies: High drug cost may restrict access initially.
• Patient monitoring: Caution needed for adverse events such as systolic heart failure and arrhythmias observed in trials.
• Competitive landscape: Bayer's MYK-461 (similar mechanism) and future pipeline drugs.

---

3. What Is the Financial Trajectory of Mavacamten?

Revenue Projections

Year	Estimated U.S. Revenue	Estimated Global Revenue	Assumptions
2023	$200 million	$250 million	Steady adoption post-launch, clinical awareness.
2024	$500 million	$600 million	Increased awareness, expanding indications.
2025	$1.2 billion	$1.4 billion	Broader adoption, payor coverage, indication expansion.
2026	$2.0 billion	$2.2 billion	Global expansion, combination therapy potential.

(Note: These figures are based on market modeling, prevalence, price points, and uptake rate assumptions.)

Cost and Investment Considerations

• Manufacturing: Scaled to meet global demand, with ongoing R&D for pipeline development.
• Marketing: Investment in physician education and patient advocacy groups.
• Regulatory: Potential for label expansion (e.g., non-obstructive HCM) to increase revenue.
• Profitability timeline: Expected to reach profitability by 2024-2025, contingent on uptake and pricing.

---

4. How Does Mavacamten Compare to Competitors?

Feature	Mavacamten	Bayer's MYK-461	Emerging Agents
Mechanism	Selective cardiac myosin inhibition	Same	N/A
Indications	Obstructive HCM	Obstructive HCM	Non-obstructive HCM, HFpEF (under trial)
Regulatory Status	Approved (FDA, EMA)	Clinical trials	Preclinical / early phase
Market Position	First-in-class, targeted therapy	Similar, late-stage	Potential new entrants

Summary: Mavacamten's unique mechanism and first-mover advantage position it favorably, but competition may gain ground with pipeline drugs and combination therapies.

---

5. What Strategic Opportunities and Risks Exist?

Opportunities	Risks
First-mover advantage and established clinical data	Market size may be limited if prevalence estimates are inaccurate
Expansion into non-obstructive HCM and other cardiac conditions	High development costs and regulatory hurdles
Strategic collaborations with payors and healthcare providers	Competition from emerging therapies targeting similar pathways
Increasing global adoption driven by EU and Asia approvals	Price sensitivity and reimbursement challenges

---

Comparison Table: Key Financial and Market Parameters

Parameter	Value/Estimate	Notes
Prevalent U.S. oHCM cases	~27,000	1 in 500 HCM, ~60% obstructive
Target Patient Population (globally)	~200,000	Estimated based on prevalence
Price per treatment (monthly)	~$10,000	Current WAC
Annual treatment cost per patient	~$120,000	Assuming continuous therapy
Market size (initial year)	~$700 million (U.S.)	Based on estimated patient numbers and prices
Peak global revenues (2030)	~$2 billion	With pipeline expansion

---

Conclusion: Investment Outlook for Mavacamten

Mavacamten presents a compelling opportunity as a first-in-class therapies targeting oHCM with a significant unmet clinical need. The licensing and approval trajectory has laid a foundation for sustained revenue growth, with projections indicating a multi-billion-dollar market within a decade. Strategic expansion into additional indications, coupled with favorable payer dynamics, supports a positive financial outlook. However, competitive development, high R&D costs, and market access challenges necessitate careful risk management.

---

Key Takeaways

• Market Potential: Mavacamten targets a niche but underserved cardiac condition with an estimated peak global revenue potential exceeding $2 billion annually.
• Regulatory Status: As the first approved drug specifically for oHCM, mavacamten benefits from a significant first-mover advantage.
• Revenue Trajectory: Revenue is projected to grow rapidly from 2023 onward, reaching profitability by mid-2020s.
• Competitive Position: Although early, mavacamten's mechanism and clinical data suggest durable market dominance if pipeline and expansion strategies succeed.
• Risks: Market access, reimbursement, competition, and broader indication approval remain key dependencies.

---

FAQs

Q1: What is the primary clinical benefit of mavacamten?
A1: Mavacamten reduces left ventricular outflow tract obstruction, alleviating symptoms and improving exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Q2: How does mavacamten’s pricing compare with similar drugs?
A2: Currently, the wholesale acquisition cost is approximately $10,000 per month, aligning with other targeted cardiovascular therapies but potentially limiting access initially due to high cost.

Q3: What are the main regulatory hurdles for expanding mavacamten’s indications?
A3: Demonstrating safety and efficacy in non-obstructive HCM and heart failure populations, alongside successful clinical trial outcomes, are critical for regulatory approval.

Q4: How does the competitive landscape look for mavacamten?
A4: While mavacamten is first-in-class for oHCM, Bayer’s MYK-461 and emerging agents in late-stage trials could pose future competition.

Q5: What is the primary risk factor that could impact mavacamten’s market success?
A5: Reimbursement challenges and high drug costs could hinder patient access unless adequately managed through payer negotiations and value demonstration.

---

References

[1] FDA Drug Approval Announcement, April 2022.
[2] Bristol-Myers Squibb Press Release, 2020.
[3] Maron BJ et al., Circulation, 2006.
[4] Olivotto I et al., Circulation: Cardiovascular Genetics, 2012.